Free Trial

Harrow Q1 2023 Earnings Report

Harrow logo
$36.10 +2.25 (+6.65%)
As of 01/21/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Harrow Revenue Results

Actual Revenue
$26.10 million
Expected Revenue
$25.89 million
Beat/Miss
Beat by +$210.00 thousand
YoY Revenue Growth
N/A

Harrow Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Harrow Earnings Headlines

Harrow announces Amir Shojaei, PharmD, PhD joins as CSO
Harrow Health (HROW) Gets a Buy from Craig-Hallum
Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
Those Derisked Baby Bonds Of Harrow, Inc.
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat